Breaking Gene Therapy News
-
Researchers report longest duration of therapeutic gene expression - EurekAlert
Jun 17, 2019 | 22:24 pmResearchers report longest duration of therapeutic gene expression EurekAlertNew Rochelle, NY, June 14, 2019--A therapeutic gene delivered into the spinal canal of infant rhesus monkeys was still being expressed after nearly 4 years, ...
Read more... -
Gene therapy delivers hope to Blountstown baby at Shands hospital - Tallahassee.com
Jun 17, 2019 | 21:32 pmGene therapy delivers hope to Blountstown baby at Shands hospital Tallahassee.comOn June 7, Londyn became the first baby in the country treated with a newly approved gene therapy for a rare and debilitating neuromuscular disease.
Read more... -
Shares of cancer-therapy companies skyrocket after Pfizer acquisition news - MarketWatch
Jun 17, 2019 | 19:30 pmShares of cancer-therapy companies skyrocket after Pfizer acquisition news MarketWatchShares of gene-therapy companies shot up on Monday after Pfizer Inc. announced it would acquire cancer drug maker Array BioPharma Inc. in a deal worth up ...
Read more... -
Sanofi, Voyager Therapeutics rejig gene therapy partnership - MedCity News
Jun 17, 2019 | 19:16 pmSanofi, Voyager Therapeutics rejig gene therapy partnership MedCity NewsVoyager Therapeutics Announces Restructured Gene Therapy Relationship with Sanofi Genzyme and Portfolio Update GlobeNewswireVoyager Therapeutics to restructure Sanofi gene therapy deal Seeking AlphaVoyager Revises Sanofi Deal, Shifts Some Assets BioSpaceView full coverage on Google News
Read more... -
Bluebird Bio prices gene therapy at $1.8M - Becker's Hospital Review
Jun 17, 2019 | 17:12 pmBluebird Bio prices gene therapy at $1.8M Becker's Hospital ReviewBluebird Bio has priced Zynteglo, its gene therapy for a blood disorder, at $1.8 million, according to STAT news.
Read more... -
UPDATED: Sanofi Genzyme deserts gene therapy developer Voyager Therapeutics - Endpoints News
Jun 17, 2019 | 16:06 pmUPDATED: Sanofi Genzyme deserts gene therapy developer Voyager Therapeutics Endpoints NewsAlbert Bourla appears before the Senate Committee on Finance for a hearing on prescription drug pricing on Capitol Hill in Washington, DC, February 26, 2019.
Read more... -
PreveCeutical Medical reports positive results from its dual gene therapy research program - Proactive Investors USA & Canada
Jun 17, 2019 | 15:57 pmPreveCeutical Medical reports positive results from its dual gene therapy research program Proactive Investors USA & CanadaPreveCeutical Medical Inc (CNSX:PREV) - The Vancouver health science company says it has successfully identified and finalized a panel of 'highly potent and ...
Read more... -
IVERIC bio Enters into Strategic Manufacturing Relationship with Catalent's Paragon Gene Therapy for Orphan Inherited Retinal Diseases - Yahoo Finance
Jun 17, 2019 | 15:28 pmIVERIC bio Enters into Strategic Manufacturing Relationship with Catalent's Paragon Gene Therapy for Orphan Inherited Retinal Diseases Yahoo FinanceIVERIC bio, Inc. and Catalent Biologics, today announced that they have entered into an agreement for production and manufacturing of GMP-grade ...
Read more... -
UniQure weighs sale after hemophilia gene therapy turnaround: report - FierceBiotech
Jun 17, 2019 | 13:50 pmUniQure weighs sale after hemophilia gene therapy turnaround: report FierceBiotechGene Therapy Player Uniqure Could Be Acquired; Biotech Company's Stock Pops Investor's Business DailyGene-therapy firm UniQure explores options including sale The Business TimesUniQure shares hit record high after news report of potential sale BioPharma DiveUniQure Exploring Possible Sale, Report Says BioSpaceView full coverage on Google News
Read more... -
Novartis’ new $2.1 million drug has roots in Philadelphia. Here’s how the city has impacted treatment of rare - The Philadelphia Inquirer
Jun 17, 2019 | 12:04 pmNovartis’ new $2.1 million drug has roots in Philadelphia. Here’s how the city has impacted treatment of rare The Philadelphia InquirerThe latest million-dollar drug and the emerging gene therapy field it's part of have a Philadelphia origin story.
Read more... -
Continuous bioprocessing – the key to industrialising gene therapy production? - pharmaphorum
Jun 17, 2019 | 11:20 amContinuous bioprocessing – the key to industrialising gene therapy production? pharmaphorumA new partnership aims to investigate the possibility of using continuous manufacturing processes in gene therapy.
Read more... -
Gene therapy R&D deals turn red hot as Big Pharma steps up to play - Endpoints News
Jun 17, 2019 | 10:07 amGene therapy R&D deals turn red hot as Big Pharma steps up to play Endpoints NewsUnlock this article along with other benefits by subscribing to one of our paid plans. SUBSCRIBE SIGN IN. Albert Bourla appears before the Senate Committee ...
Read more... -
New Gene Therapy Priced at $1.8 Million in Europe - The Wall Street Journal
Jun 14, 2019 | 18:18 pmNew Gene Therapy Priced at $1.8 Million in Europe The Wall Street JournalThe maker of a gene therapy for a rare blood disorder said it would sell the new treatment for €1.6 million ($1.8 million) in Europe, a sticker price that indicates ...
Read more... -
Bluebird's gene therapy will cost $1.8 million. Cue the price debate - STAT
Jun 14, 2019 | 14:03 pmBluebird's gene therapy will cost $1.8 million. Cue the price debate STATZynteglo, the one-and-done gene therapy for beta thalassemia newly approved in Europe, will carry a price tag of $1.8 million, Bluebird announced.
Read more... -
SMA Gene Therapy Zolgensma 'Saved All of Our Lives': A Family's Story - SMA News Today
Jun 14, 2019 | 14:00 pmSMA Gene Therapy Zolgensma 'Saved All of Our Lives': A Family's Story SMA News TodayTina and Torence Anderson share the story of their son, Malachi, who has SMA type 1 and became one of the first babies treated with Zolgensma.
Read more... -
Gene therapy costs, manufacturing keeping CBER head 'up at night' - BioPharma Dive
Jun 13, 2019 | 20:00 pmGene therapy costs, manufacturing keeping CBER head 'up at night' BioPharma DivePeter Marks, head of the Food and Drug Administration's Center for Biologics Evaluation and Research, said his top concern for gene therapy's future is ...
Read more... -
How will we pay for potentially curative gene therapies? - STAT
Jun 12, 2019 | 10:46 amHow will we pay for potentially curative gene therapies? STATWe have arrived at a special moment in health care. Innovative, life-changing gene therapies are here that will cure or ease debilitating diseases. Yet these ...
Read more... -
The gene therapy era has arrived. So have the challenges. - BioPharma Dive
Jun 7, 2019 | 09:00 amThe gene therapy era has arrived. So have the challenges. BioPharma DiveA landmark regulatory approval has vaulted the cell and gene therapy space to the front of the drug industry's mind. But speedy progress has also brought ...
Read more... -
Gene Therapy Appears to Be Beating Once-Incurable Diseases - Bloomberg
Jun 5, 2019 | 09:00 amGene Therapy Appears to Be Beating Once-Incurable Diseases BloombergGene therapy appears to successfully treat once-incurable patients like “bubble boy” Omarion Jordan. But progress like this doesn't come cheap.
Read more... -
Gene therapy gets FDA approval -- and a $2 million price tag - CNN
May 24, 2019 | 09:00 amGene therapy gets FDA approval -- and a $2 million price tag CNNThe US Food and Drug Administration approved a treatment Friday for a genetic disease called spinal muscular atrophy that causes infants' muscles to waste ...
Read more...